Pay in 4 interest-free payments of $5.93 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
After RXR heterodimerization, the agonist ligand activates FXR, which then binds to FXR response elements and regulates target gene expression
Researchers continue to investigate BPC-157 due to its apparent involvement in multiple biological signaling pathways rather than a single molecular target
Lyophilized: 12-24 months
Most common adverse events at all doses: Nausea (15-30%, dose-related) Vomiting (5-15%) Decreased appetite (~20%) Constipation (5-12%) Cagrilintide-specific notes: A 2025 Bayesian network meta-analysis of incretin-based therapies reported cagrilintide had one of the lowest GI odds ratios across the studied compound class
Related research Researchers working with BPC-157 often cross-reference adjacent mechanistic and assay literature
Managing GI effects comes down to a few practical approaches
US$ 27.28
US$ 25.18
US$ 26.69
US$ 29.56
US$ 27.64
US$ 23.11
US$ 26.80
US$ 25.69
US$ 25.49
US$ 26.48
US$ 25.36
US$ 25.41
